Inhibition of Kaposi’s Sarcoma in Vivo by Fenretidine

Nicoletta Ferrari, Monica Morini, Ulrich Pfeffer, Simona Minghelli, Douglas M. Noonan, and Adriana Albini

1Molecular Oncology Laboratory and 2Tumor Progression Section, the National Institute for Cancer Research and the 3Advanced Biotechnology Center, Genova, Italy

ABSTRACT

Purpose: We examined the effects of fenretinide [N-(4-hydroxyphenyl)retinamide; (4HPR)] on highly angiogenic Kaposi’s sarcoma tumors in vivo and investigated the mechanisms involved for potential clinical applications.

Experimental Design: (CD-1)BR nude mice bearing KS-Imm cell tumors were randomized to receive 4HPR or vehicle until sacrifice. In vitro, KS-Imm and endothelial cells were treated with 4HPR to study the effects on proliferation, apoptosis, migration, and invasion; in vivo angiogenesis was evaluated in the Matrigel model. Angiogenesis-related and retinoid receptor molecules were examined at the mRNA and protein expression levels.

Results: In vivo, 4HPR significantly (P < 0.001) reduced growth of detectable Kaposi’s sarcoma (KS) xenografts and inhibited angiogenesis in the Matrigel plug assay (P < 0.04). In vitro, 4HPR affected KS-Imm and endothelial cell growth and KS-Imm migration and invasion. 4HPR invasion inhibition was associated with decreased release of matrix metalloprotease-2 and rapid reduction of vascular endothelial growth factor (VEGF) expression by KS cells and of vascular endothelial growth factor receptor 2 (VEGFR2) by KS and endothelial cells. Finally, 4HPR repression of angiogenesis was associated with a 4HPR-induced increase in retinoic acid receptor β expression.

Conclusions: These data indicate that 4HPR inhibits KS tumor growth in vivo through a mechanism involving the modulation of angiogenesis-associated growth factors and their receptors on both tumor and endothelial cells. In addition, 4HPR inhibited invasion by decreasing of matrix metalloprotease-2 activity. Our results justify further studies to evaluate the utility of 4HPR as a chemopreventive or therapeutic agent in KS, a malignancy associated with immune suppression that has a high risk of recurrence with highly active antiretroviral therapy failure.

INTRODUCTION

KS, a highly vascularized tumor associated with infection by the KS-associated herpesvirus/HHV8 (1), is the most common tumor associated with human immunodeficiency virus infection, which develops in 15–30% of cases during the course of AIDS (2). KS contributes to morbidity and mortality through invasion of the lungs, the gastrointestinal tract, and other visceral organs. Although the use of highly active antiretroviral therapy (HAART) has led to decreased KS tumor incidence and burden in AIDS-KS patients, the risk for recurrence of KS, once HAART is discontinued, is very high. KS is also associated with therapeutic immune suppression in HHV8-infected patients. In geographical areas where a high endemic HHV8 infection rate overlaps with widespread, inadequately treated HIV infection, KS has become the leading tumor type (3).

The main histological features of KS are spindle cells, an inflammatory infiltrate, and the formation of a dense, poorly organized capillary network recruited from the host (2). KS spindle cells release a mixture of potent stimulators of endothelial cell migration and invasion (4) that induce angiogenesis in vivo (5). The process of angiogenesis is tightly regulated, depending on a dynamic balance between stimulators and inhibitors. In the early 1970s, inhibition of angiogenesis was proposed as a possible strategy for the treatment of solid tumors (6), and the search for mediators and inhibitors of tumor angiogenesis began (7). Recently, we have noted that numerous drugs used as cancer chemoprevention agents appear to target tumor angiogenesis, suggesting that this may be a main mechanism for this class of molecules (8).

Retinoids have been shown to exert chemopreventive and antitumor activities in a variety of normal and malignant cells (9–11). RA and 9-cis-RAs have produced tumor responses in KS both in vitro and in vivo (12–14). RA does not control recurrences of the original tumor but can block the development of new primary tumors (15). The vitamin A analogue fenretinide (4HPR) has been shown to inhibit breast carcinogenesis in preclinical studies (16), and premenopausal women treated with 4HPR have shown a significantly lower incidence of new breast cancers than the corresponding control group in a clinical trial

The abbreviations used are: KS, Kaposi’s sarcoma; HHV, human herpesvirus; HAART, highly active antiretroviral therapy; RA, retinoic acid; fenretinide, [N-(4-hydroxyphenyl)retinamide (4HPR)]; CAM, chorio-allantoic membrane; RAR, retinoic acid receptor; RXR, retinoid X receptor; AP, activator protein; VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinase; VEGFR, vascular endothelial growth factor receptor; FGF, fibroblast growth factor; SFM, serum-free medium; CM, conditioned medium; TNF, tumor necrosis factor; VTH, 100 ng/ml VEGF, 2 ng/ml TNFα, and heparin; RT, reverse transcription; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
These patterns are typical of anti-angiogenic agents that prevent further development of hidden metastases, even if they are unable to control growth of the original primary tumor (18).

Several studies have indicated that retinoid treatment is associated with angiogenesis inhibition and a decreased vascular response in vitro and in vivo (19–23). In particular, it has been shown that 4HPR is capable of inhibiting angiogenesis in the chick CAM assay (24, 25), an activity associated with several different potential mechanisms; it has also been shown that 4HPR represses tumor growth in vivo in prevention protocols (24).

Retinoids exert their effects through two families of nuclear receptors, RARs and RXRs, which are ligand-dependent transcription factors belonging to the superfamily of steroid-thyroid-vitamin D₃ hormone receptors. Retinoid receptors activate gene expression by binding to response elements present in the promoter regions of RA-responsive genes (26). Retinoid receptors have also been shown to negatively regulate the expression of certain genes by antagonism of the activity of transcription factor AP-1 (27).

Here we demonstrate that administration of 4HPR potently inhibited growth of established KS tumors in vivo in early intervention protocols. This activity was associated with decreased tumor vessel density, repression of the proangiogenic release of VEGF and MMP-2 by the tumor cells, as well as reduced endothelial cell proliferation and VEGFR2 expression. The 4HPR-mediated down-regulation of angiogenesis may be RARβ-dependent, because RARβ expression was strongly induced by fenretinide, whereas other retinoids that did not effect cell growth in vitro or angiogenesis in vivo were unable to induce RARβ expression. Our studies indicate that 4HPR may be useful in the prevention and therapy of KS.

MATERIALS AND METHODS

Cell Culture and Chemicals. The previously described KS-Imm cell line, isolated in our laboratory from a kidney transplanted immuno-suppressed patient (28), was grown in RPMI containing 10% FCS and 1% glutamine. Endothelial HUVE cells were obtained from the ATCC (Rockville, MD) and cultivated on gelatin coated plates (1% in PBS) in M199 containing 10% heat-inactivated FCS, 10 ng/ml heparin, 10 ng/ml acidic FGF, 10 ng/ml basic FGF, 10 ng/ml epidermal growth factor, 10 μg/ml hydrocortisone. 4HPR (Fenretinide; Calbiochem, La Jolla, CA) was dissolved in absolute ethanol at a stock concentration of 10 mM and stored in aliquots at −70°C.

Tumor Growth in Vivo. The effect of 4HPR on the KS growth in vivo was tested by using 18 seven-week-old male (CD-1)BR nude mice (Charles River, Lecco, Italy) having an average weight of ~25 g, housed in pathogen-free conditions. KS-Imm cells at 80% confluence were harvested by trypsinization, counted and resuspended in SFM. The cells (5 × 10⁴) were then mixed with liquid Matrigel (10 mg/ml) to a final volume of 250 μl at 4°C and injected s.c. into the flanks of nude mice. Ten days after tumor cell injection, when a distinct tumor mass was detectable in all animals, the animals were randomized into three groups with the same average tumor size in an early intervention protocol. Each group was given daily an intragastric administration of 100 μl sesame seed oil either alone (control group) or containing 1.2 mg/kg or 12 mg/kg body weight of 4HPR, based on previous studies (24). The animals were weighed and the tumor diameters measured every 2–3 days. Animals were sacrificed after 14 days of treatment, and the tumor was removed and processed for histological evaluation. Vessel densities were estimated by counting the vessels in stained sections. Random fields were selected for section of several different tumors derived from control and treated animals. Housing and treatments of animals were in accordance with the Italian National and European Community guidelines (D.L. 2711/92 No. 116; 86/609/EEC Directive).

Cell Proliferation and Apoptosis Assays. To study cell growth, 750 KS-Imm or 2,000 HUVE cells per well were seeded in 96-well plates and grown in complete medium or treated with various concentrations of 4HPR. Media were changed every 48 h and the number of viable cells was measured with the crystal violet assay. Briefly, after fixation and staining in a solution of 0.75% crystal violet, 0.35% sodium chloride, 32% ethanol, and 3.2% formaldehyde, the cells were dissolved in 50% ethanol, 0.1% acetic acid, and read at 595 nm. To measure any enrichment of cytoplasmic histone-associated DNA fragments after 4HPR-induced cell death, a commercially available kit was used (Cell Death Detection ELISA, Roche, Roche, Mannheim, Germany) using 24-well plates seeded with 10,000 (KS-Imm) or 30,000 (HUVE) cells per well and grown in complete medium with various concentrations of 4HPR.

Chemotaxis and Invasion Assays. Chemotaxis and chemo-invasion assays on KS-Imm cells were carried out in Boyden chambers as described previously (29). KS-Imm cells were exposed to different concentrations of 4HPR for 15 h in SFM with 0.1% BSA. Trypan blue exclusion under these conditions showed no decreased cell viability as compared with controls. After treatment, 5 × 10⁴ cells in SFM with 0.1% BSA were placed in the upper compartment with or without 4HPR as a control. The two compartments of the Boyden chamber were separated by a 8-μm pore-size polycarbonate filters coated with 0.3 mg/ml gelatin for the chemotaxis assay or with Matrigel (15 μg/ml), a reconstituted basement membrane, for the invasion assay. Supernatants from NIH3T3 cells (NIH3T3-CM) were used as chemo-attractants in the lower chamber. After 6 h of incubation at 37°C in 5% CO₂, the filters were recovered, the cells on the upper surface were mechanically removed and those on the lower surface were fixed and stained. The migrated cells were counted in 5–10 fields for each filter under a microscope. The experiments were performed in triplicate and repeated three times.

In Vivo Angiogenesis. We used the Matrigel sponge model of angiogenesis described previously (5). KS-CM and heparin or VTH (100 ng/ml VEGF, 2 ng/ml TNFα, and heparin) either alone or in combination with 4HPR were added to unpolymerized liquid Matrigel at 4°C and the mixture brought to a final volume of 600 μl. The Matrigel suspension was then injected slowly s.c. into the flanks of C57/B6 male mice (Charles River, Lecco, Italy) with a cold syringe. At body temperature in vivo, the Matrigel quickly polymerizes to form a solid gel. Different groups of animals (four mice in each group) were used for the different treatments. The control group was treated with vehicle alone and provided plain drinking water ad libitum. One group received 4HPR (5 μM final concentration)
only in the Matrigel sponge, whereas another group was given 4HPR in the drinking water (12 mg/kg/day) three days before Matrigel injection and continued 4 days after. A third group received both oral and Matrigel incorporated 4HPR treatments. After 4 days, gels from all groups were collected and weighed. Samples were either minced and diluted in water to measure the hemoglobin content with a Drabkin reagent kit (Sigma, Milano, Italy) or processed for histology.

**Gelatin Zymography.** Supernatants of cells incubated for 20 h in regular SFM with 0.1% BSA or in the presence of different concentrations of 4HPR were removed and pelleted by centrifugation. The protein content was measured by the Bradford method (Bio-Rad, Hercules, CA) and gelatin zymography performed as described previously (30). Briefly, SDS-PAGE gels were prepared containing copolymerized gelatin at a final concentration of 1.6 mg/ml. After electrophoresis, the gels were washed in 2.5% Triton X-100 for 30 min to remove SDS and incubated for 18 h at 37°C in collagenase buffer [40 mM Tris, 200 mM NaCl, and 10 mM CaCl2 (pH 7.5)]. Gels were then stained in 0.1% Coomassie brilliant blue followed by destaining. The enzyme-digested regions were observed as white bands against a blue background.

**RNA Extraction, RT-PCR, and Real-time RT-PCR.** Total RNAs were isolated from control and treated cells that were grown in complete medium using the RNasy Mini Kit (Qiagen, Milano, Italy). RT was performed with oligodeoxythymidylic acid primers and PCR for each VEGF antisense, 5'-TGTCTCCCAGCCTGATG; VEGF sense, 5'-GACGCAGTTCAATCGGTATGC; VEGF antisense, 5'-GCAGCAGTTGGTTCTGTATC; VEGF-B sense, 5'-TGCTTCGCCAGCTGATG; VEGF-B antisense, 5'-AGTCAAGGGCACCACCA; RAR-β sense, 5'-TCTCAGCTGGGAGTCGTT; RAR-β antisense, 5'-GCTGGTGCCTCTGTTGCCAA. Relative expression of each gene was assessed in comparison to the housekeeping gene GAPDH amplified with the primers: sense 5'-GAAGGTTAGGCTGGGAT and antisense 5'-CATTGGTTGAAATCATATGGAA. cDNAs were amplified for 50 cycles using iQ Supermix (Bio-Rad, Hercules, CA) containing the intercalating agent SYBR Green in a two-step amplification scheme (95°C, 15 s; 60°C, 30 s). Fluorescence was measured during the annealing step on a Bio-Rad iCycler iQ instrument (Bio-Rad, Hercules, CA). Blank controls that did not contain cDNA were run in parallel. All samples were run in triplicate. After amplification, melting curves with 80 steps of 15 s and a 0.5°C temperature increase were performed to control for amplification. Relative expression values with standard errors and statistical comparisons (unpaired two-tailed t test) were obtained using Qgene software (32).

**Protein Extraction, Immunoprecipitation, and Western Blotting.** KS-Imm and HUVE cells were grown in 100-mm culture dishes in regular media in the presence or absence of 5 μM 4HPR for the indicated times. Cellular proteins were isolated in lysate buffer containing 6 M urea, 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 5% β-mercaptoethanol, and 10% glycerol. Samples containing 50 μg of proteins as determined by Bradford analysis were subjected to electrophoresis and transferred to Hybond ECL membranes (Amersham, Milano, Italy). For Western blotting, membranes were blocked in 5% nonfat milk in Tris-buffered saline with 0.1% Tween 20 for 1 h at room temperature and then incubated for 3 h with an anti-VEGFR2 antibody (Santa Cruz Biotechnology, Santa Cruz Biotechnology, CA) at room temperature. The membranes were subsequently incubated for 1 h with peroxidase-labeled secondary antibody (Amersham, Milano, Italy) and specific complexes were revealed by enhanced chemiluminescence solution (Amersham, Milano, Italy). For VEGF detection, KS-Imm cells were grown as above and during the last 8 h were labeled in 1.5 ml of methionine and cysteine-free MEM containing 2 μCi glutamine, 10% dialyzed FCS, and 100 μCi 35S-trans label (ICN, Irvine, CA). Culture media were collected, centrifuged at maximum speed, and preclotted with a 1:1 suspension of Protein A-Sepharose in PBS for 2 h at 4°C. Immunoprecipitation on the same amounts of radiolabeled material was then performed at 4°C overnight with a mouse monoclonal antihuman VEGF antibody (Sigma, Milano, Italy) and 50 μl of Protein A-Sepharose in PBS. The immunoprecipitated protein was washed three times in radioimmunoprecipitation assay buffer, once in PBS, and eluted from the resin with 20 μl of SDS sample buffer at 100°C for 2 min. The eluted protein was loaded on 12.5% SDS-polyacrylamide gels and electrophoresed. Gels were then dried under vacuum and exposed to Hyperfilm MP (Amersham, Milano, Italy).

**VEGF Quantification by ELISA.** VEGF protein released into the media by KS-Imm cells was measured using a commercial ELISA kit (LISTARFISH; CYTImmune Sciences, College Park, MD) following the manufacturer’s instructions. The supernatants from cells grown in complete medium either without or with 0.1, 1, and 5 μM 4HPR were collected after 24 or 48 h. The ELISA assay was performed on 100 μl, and the values obtained were compared with a calibration curve prepared by serial dilution of standard VEGF in complete medium. The assay was run in triplicate and repeated with similar results.

**Stable Transfections.** The RARβ cDNA was cloned into the pZeosV expression vector as described previously (33). Empty vector and the RARβ-expressing vectors were transfected into KS-Imm cells with Lipofectamine 2000 (Invitrogen, Irvine, CA). Stable transfectants were isolated by selection with 400 μg/ml of Zeocin (Invitrogen, Irvine, CA), and the total pool of transfectants was used.

**RESULTS**

**4HPR Inhibition of KS Growth in Nude Mice.** KS-Imm cells formed highly vascular tumors when injected s.c. into nude mice, with tumor masses becoming detectable and measurable ~10 days after injection. At this time, animals were randomized into groups with the same average tumor volume and 4HPR treatment was started. Animals that were treated with a daily intragastric treatment of 12 mg/kg body weight 4HPR in sesame seed oil showed reduced tumor growth as compared with controls, which formed large tumors (Fig. 1). No alteration of tumor growth was observed for animals treated with 1.2 mg/kg 4HPR. Comparison of tumor growth curves by two-way ANOVA showed that the differences between controls and 12 mg/kg 4HPR-treated animals were statistically significant from day 20 on (P < 0.001). No differences were noted in animal...
body weights, indicating little or no toxicity of the 4HPR treatment. Histological examination showed extensive vascularization of the tumors in the control (Fig. 1) and 1.2 mg/kg 4HPR-treated animals (Fig. 1), whereas tumors in the 12 mg/kg 4HPR-treated animals showed very little vascularization (Fig. 1). Vessel counts showed a significantly (ANOVA: \( P < 0.001 \)) reduced microvessel density in the tumors that formed in the 12 mg/kg 4HPR-treated animals (2.07 vessels/unit field) as compared with controls (7.9 \pm 2.3 vessels/unit field). These data indicated that repression of angiogenesis had an important role in the inhibition of tumor growth observed.

**In Vitro Effects of 4HPR on KS-Imm and Endothelial Cells.** To determine the action of 4HPR on cell proliferation, KS-Imm cells were treated with a range of concentrations of 4HPR (from 10 nM to 5 \( \mu \)M) and the cell number assessed. Cell growth inhibition was apparent after 4 days of exposure to 5 \( \mu \)M 4HPR, which became more evident at day 7 (two-way ANOVA: \( P < 0.001 \); Fig. 2A). 4HPR was also tested for its potential to induce apoptosis by determination of cytoplasmic histone-associated DNA fragments. No significant differences between controls and treated cells were observed even at the highest concentrations used (Fig. 2B).

Because angiogenesis is required for solid tumor growth and tumors from the 12 mg/kg 4HPR-treated animals showed reduced vessel densities, we also examined the effects of 4HPR on endothelial cells in vitro. A concentration of 5 \( \mu \)M 4HPR potently inhibited endothelial cell growth with significant differences with respect to controls (two-way ANOVA: \( P < 0.001 \)) from 24 h to the end of the experiment (Fig. 2C). A concentration of 1 \( \mu \)M 4HPR also strongly and significantly inhibited HUVE cell growth (\( P < 0.001 \)) at later time points (5 and 7 days). Only a small percentage of cells underwent apoptosis after 24 h of exposure to 4HPR, whereas longer treatment times with 5 \( \mu \)M 4HPR significantly (ANOVA: \( P < 0.001 \)) reduced cellular apoptosis (Fig. 2D). Prolonged exposure to 5 \( \mu \)M 4HPR (up to 2 weeks) protected cells from apoptosis; these remained viable, yet grew at a lower rate (data not shown).

**Effect of 4HPR on Gelatinolytic Activity Released by KS-Imm Cells.** Because invasion of basement membranes requires metalloproteases, which are essential to the invasive process, we tested whether 4HPR could inhibit the gelatinase activity associated with these enzymes. Zymographic evaluation was performed on supernatants of cells incubated for 20 h in the absence or presence of increasing concentrations of 4HPR.
4HPR Inhibits Angiogenesis

Inhibition of Angiogenesis in Vivo. The effects of 4HPR on angiogenesis-associated endothelial cell functions observed in vitro were then confirmed in vivo in the Matrigel angiogenesis assay. Matrigel suspensions containing either KS cell conditioned media (KS-CM) or a cocktail (VTH) of VEGF (100 ng/ml) and TNFα (2 ng/ml) as angiogenic stimuli were injected s.c. into mice. The presence of KS-CM or VTH in the Matrigel sponges promoted a hemorrhagic vascularization of the gels within 4 days. Quantification of the extent of angiogenesis by hemoglobin content measurement showed that 4HPR treatment significantly (Mann-Whitney:  Fig. 4A) confirmed the effects of 4HPR, as assessed by the Cell Death Detection ELISA assay. No significant differences were observed. C, HUVE cell growth in vitro; at 1 and 5 μM, 4HPR significantly inhibited cell growth. D, HUVE cell apoptosis in the presence of 4HPR; after 72 h of treatment, 5 μM 4HPR significantly reduced apoptosis as compared with controls. Means ± SD are shown.

KS-Imm cells produced a characteristic gelatinase activity corresponding to the 62-kDa activated form of gelatinase A (MMP-2). Treatment with 4HPR decreased MMP-2 activity produced by KS-Imm cells in a dose-dependent manner (Fig. 3).

Modulation of VEGF and VEGFR2 Receptor by 4HPR. Because VEGF is a key angiogenic factor released by tumor cells in response to hypoxia, we examined the effects of 4HPR on the expression of VEGF in KS-Imm cells. Quantitative analysis by real-time RT-PCR revealed that exposure of KS-Imm cells to 5 μM 4HPR for 4 h significantly decreased the mRNA levels for VEGF (unpaired two-tailed t test:  P < 0.05; Fig. 5A). A significant decrease in VEGF-B (unpaired two-tailed t test:  P < 0.001; Fig. 5A) required 24 h of exposure to 5 μM 4HPR. The effects of 5 μM 4HPR on VEGF after 4 h with quantitative RT-PCR was consistent with observations in Northern blot analyses (data not shown).

VEGF protein can be detected in culture supernatants of KS-Imm cells and, under reducing conditions, the major VEGF proteins secreted have a molecular mass of 23 kDa, corresponding to glycosylated VEGF165, and 18 kDa, corresponding to glycosylated VEGF121. Immunoprecipitation of VEGF from supernatants of 35S-labeled KS-Imm cells showed that 24 h of treatment with 5 μM 4HPR reduced VEGF secretion (Fig. 5B). Lower 4HPR concentrations had little effect (data not shown). Using a sensitive ELISA system, we observed that KS-Imm cells released a mean of 252 ± 6.5 pg of VEGF/10^6 cells into the culture medium after incubation for 24 h. Treatment of KS-Imm cells with 5 μM 4HPR significantly (Student’s t test:  P < 0.025) reduced VEGF levels to 50% of the control values (130 ± 37.2 pg/10^6 cells). Forty-eight hours of 4HPR treatment also induced a striking decrease in VEGF levels (from 312 ± 8.1 to 199 ± 7.7 pg/10^6 cells; Student’s t test:  P < 0.005).

Fig. 2 A, KS-Imm cell growth in vitro in the presence of increasing doses of 4HPR, as assessed by the crystal violet assay: at 5 μM, 4HPR significantly inhibited cell growth. B, KS-Imm apoptosis in the presence of 4HPR, as assessed by the Cell Death Detection ELISA assay. No significant differences were observed. C, HUVE cell growth in vitro; at 1 and 5 μM, 4HPR significantly inhibited cell growth. D, HUVE cell apoptosis in the presence of 4HPR; after 72 h of treatment, 5 μM 4HPR significantly reduced apoptosis as compared with controls. Means ± SD are shown.

Fig. 3 Inhibition of KS-Imm cell migration and invasion (top panels) by increasing doses of 4HPR. SFM and supernatants of NIH3T3 fibroblasts were used as negative and positive controls, respectively. Experiments were performed in triplicate and repeated three times, means ± SD are shown. 4HPR inhibited both migration and invasion. Bottom, zymographic detection of secreted gelatinase activity. Supernatants of cells treated for 20 h with various concentrations of 4HPR were analyzed by gelatin zymography at equivalent protein concentration. Gelatinolytic activity is observed as white bands on the blue-stained background of gelatin in the gel. 4HPR dose-dependently inhibited the release of enzymatic activity into the supernatants, indicating inhibition of MMP release.
VEGF-C, the only form of VEGF mRNA we found expressed by HUVE cells, remained unaltered in both HUVE and KS-Imm cells after 4HPR treatment (data not shown).

The effect of 4HPR on VEGF, a VEGF key receptor, was evaluated by Western blotting of lysates from control and 4HPR treated KS-Imm and HUVE cells. Although 4HPR treatment of both cell lines had no apparent effect on VEGFR2 mRNA levels (data not shown), treatment with 5 μM 4HPR markedly down-regulated the protein levels of VEGFR2 in HUVE cells, with a 50% decrease observed after 24 h (Fig. 6A). KS-Imm produced low amounts of VEGFR2 protein that was very low or absent levels of VEGFR2 protein. Real-time RT-PCR revealed that exposure to 4HPR dose dependently induced RARβ expression, reaching a maximum after 24 h (Fig. 7B). In contrast, 24 h of exposure to 10 μM all-trans-RA, 9- or 13-cis-RA failed to produce RARβ induction (Fig. 7B).

DISCUSSION

Gains in the knowledge of endothelial cell physiology and tumor angiogenesis are providing the necessary background for
developing effective anti-angiogenic strategies that may specifically target tumor angiogenesis by inhibiting endothelial-cell recruitment and proliferation. It is currently thought that pre-malignant lesions depend on angiogenesis for conversion into invasive cancer (35, 36). It is becoming more and more evident that angiogenesis is critical in the early stages of tumor progression (37, 38), and inhibition of angiogenesis before the “angiogenic switch” may be much more effective than inhibition of established angiogenic tumors. Chemopreventive agents may be particularly effective in angiogenesis inhibition; the “angioprevention” hypothesis suggests that angiogenesis inhibition is a common, if not critical, action of effective chemopreventive agents (8) that prevents the angiogenic switch and subsequent tumor growth.

In a prevention protocol, Pienta et al. (24) reported that 4HPR effectively inhibits the growth of prostate cancer at an early stage when given from the time of tumor cell injection. Here we show similar inhibition of detectable tumors in an early intervention protocol, where 4HPR was administered after tumor take. In addition, we show that 4HPR treatment leads to
significantly reduced vessel density in the treated tumors as compared with controls, directly implicating inhibition of angiogenesis in concert with eventual direct effects on tumor cell growth potential. These data clearly link, for the first time, the anti-angiogenic activity of 4HPR with the observations of reduced tumor growth in vivo.

We also demonstrate that 4HPR inhibited several in vitro parameters associated with angiogenesis. In agreement with previous observations (25), we observed that 4HPR reduced endothelial growth in vitro, was effective at concentrations where no toxicity was detectable, and appeared to protect endothelial cells from apoptosis. In a recent report Erdreich-Epstein et al. (39) described ceramide signaling in fenretinide-induced endothelial cell apoptosis. Depending on serum concentrations, different mechanisms can effect endothelial cell growth, and clinical trials have demonstrated that 4HPR does not induce vascular damage in humans (40). 4HPR also blocked angiogenesis in Matrigel pellets in vivo, similar to its reported anti-angiogenic activity in the chick CAM assay (24, 25). On the basis of previous studies (41), we estimate that the doses used in vivo are within the concentration range obtained in human clinical studies (42).

Although 4HPR did not strongly effect KS-Imm proliferation and apoptosis in vitro, it significantly inhibited KS-Imm cell migration and invasion toward angiogenic factors (fibroblast supernatants) similar to that reported previously for chemically transformed BALB/c 3T3 (43). MMPs appear to be involved in many stages of tumor progression, from inducing the angiogenic switch to tumor cell invasion itself (44). In contrast to the data reported for transformed BALB/c 3T3 (43), we observed that 4HPR induced a dose-dependent decrease of MMP-2 activity released by KS-Imm cells. This may be directly responsible for inhibition of invasion in vitro and may play a role in angiogenesis inhibition in vivo.

Among the network of growth factors and cytokines that regulate angiogenesis, VEGF is unique, being a potent endothelial cell-specific mitogen produced by normal and transformed cells. Augmented VEGF levels have been found in many different tumors and VEGF expression has been associated with metastasis (45). Several studies have demonstrated a role for VEGF and its receptors in the pathogenesis of KS (46, 47). Thus, therapeutic agents that target the VEGF pathway may be an effective strategy in reducing tumor growth, particularly for KS. RA and synthetic retinoids have been shown to inhibit basal expression of VEGF mRNA and block 12-O-tetradecanoylphorbol-13-acetate-induced VEGF expression in human keratinocytes (48). In contrast to the lack of effect reported for neuroblastoma (25), we found that 4HPR partially decreased the release of VEGF, which is also an autocrine growth factor for KS (47). This reduction of VEGF release by 4HPR could, in turn, limit vascularization of the tumor, resulting in reduced tumor growth. VEGF and VEGF-C are critical in regulating vascularization (49) in vivo, whereas the biological role of VEGF-B is less clear. One study (50) reported that VEGF-B expression in human primary breast cancer is associated with lymph node metastasis, but not angiogenesis, suggesting that VEGF-B may contribute to tumor progression by a nonangiogenic mechanism. Therefore, it is possible that 4HPR repression of VEGF release not only limits tumor vascularization but also tumor spread, resulting in a reduction of both tumor growth and metastasis.

In the endothelium, VEGF exerts its action through the cell surface tyrosine kinase receptors VEGFR1, VEGFR2, and VEGFR3. VEGFR1 is a higher affinity receptor, whereas VEGFR2 is more highly expressed and involved in transduction of angiogenic signals (51) potentially in concert with VEGFR3 (52). Because VEGF is crucial to physiological and pathological processes dependent on angiogenesis and is an endothelial cell survival signal, it is reasonable to predict that VEGF-receptor modulation would alter vascular cell behavior. Our results indicate that 4HPR induced down-regulation of VEGFR2 protein in endothelial and KS-Imm cells. These data are in keeping with previous immunohistochemical studies that demonstrated that 4HPR treatment reduced VEGFR2 and FGF-2R expression on the endothelial cells of the chick CAM (25) and suggest that 4HPR inhibits tumor cell angiogenic potential.

The diverse and pleiotropic effects of retinoids are mediated through their binding to a family of nuclear receptors, the RARs and the RXRs (53). Ligand-bound RARs and RXRs are able to up-regulate transcription directly by binding to RA-responsive elements on the promoters of responsive genes (26). As an indirect effect, liganded RARs and RXRs can negatively affect gene expression via their ability to functionally interact with the transcription factor AP-1 (27). The mechanisms controlling the down-regulation of VEGF and VEGFR2 in our cellular model remain to be elucidated; however, we favor the hypothesis of an RAR/RXR antagonism of AP-1, as previously reported for VEGF (48). It is tempting to speculate that RARβ plays a central role, because it was induced by 4HPR, but not by other retinoids (all-trans-RA, 9- and 13-cis-RA). This correlates with the observation that all-trans-RA, 9-, and 13-cis-RA failed to inhibit both cell growth (in vitro and in vivo) and angiogenesis in the assays used here (unpublished observations and Ref. 23). Moreover, over-expression of RARβ decreases the growth rate of KS-Imm cells, similar to that reported previously for other cell lines (33, 54). Previous studies have shown that cAMP-responsive element binding protein-binding protein (CBP) and the related p300 can act as transcriptional coactivators for both nuclear receptors (55) and AP-1 (56). On the basis of these data, we hypothesize that the gene down-regulation exerted by 4HPR depends on competition for limiting amounts of these two coactivator proteins, as already reported for VEGFR2 (57). However, we cannot rule out involvement of receptor independent mechanisms.

In summary, we show that 4HPR represses KS tumor growth in an in vivo model and that angiogenesis inhibition is a principal mechanism of this inhibition. 4HPR hindered tumor cell-induced angiogenesis at multiple levels, impairing both the angiogenic potential of the tumor cells and the ability of the host endothelial cells to respond to tumor-derived angiogenic signals by modulating specific molecules involved, including MMP-2, VEGFs, and VEGFRs, acting as an “angiopreventive” drug. These activities may well combine in vivo to play a significant role in preventing the occurrence of solid tumors. To date, there are no reports of clinical use of 4HPR in KS; our data suggest that 4HPR should be tested for potential use to assist in clinical management of KS. These scenarios include both control of established KS, such as AIDS-associated KS, particularly in
areas where HAART is not an option because of economic factors or HAART failure, and prevention of KS in HHV8 carriers subjected to immunosuppression, particularly transplant patients.

ACKNOWLEDGMENTS

We thank Drs. R. Benelli, A. Menotti, and P. Larghero for helpful discussion and F. Campelli and E. Giovanelli for the photomicrographs and technical assistance. We are grateful to M. Barabino for data management and A. Rapetti for administrative assistance.

REFERENCES

Inhibition of Kaposi's Sarcoma *in Vivo* by Fenretinide

Nicoletta Ferrari, Monica Morini, Ulrich Pfeffer, et al.


Updated version: Access the most recent version of this article at:
[http://clincancerres.aacrjournals.org/content/9/16/6020](http://clincancerres.aacrjournals.org/content/9/16/6020)

Cited articles: This article cites 50 articles, 17 of which you can access for free at:
[http://clincancerres.aacrjournals.org/content/9/16/6020.full#ref-list-1](http://clincancerres.aacrjournals.org/content/9/16/6020.full#ref-list-1)

Citing articles: This article has been cited by 7 HighWire-hosted articles. Access the articles at:
[http://clincancerres.aacrjournals.org/content/9/16/6020.full#related-urls](http://clincancerres.aacrjournals.org/content/9/16/6020.full#related-urls)

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.